Month: September 2022

Marimekko Corporation, Stock Exchange Release, 6 September 2022 at 7.46 a.m. Marimekko focuses on scaling its profitable growth during the next strategy period of 2023–2027 Marimekko intends to focus on scaling the Marimekko business and growth especially in international markets during the next strategy period of 2023–2027. The company will elaborate on the strategic direction and the new long-term financial goals published today in its Capital Markets Day on Wednesday, 14 September 2022. During the current strategy period of 2018–2022, Marimekko’s objective has been to achieve markedly stronger profitable growth than before by speaking to a broader target audience. The company’s net sales and profitability have developed strongly from year to year. Despite the challenging environment of the Coronavirus pandemic, 2021 was a record year...

Marimekko Corporation, Inside Information, 6 September 2022 at 7.45 a.m. Marimekko raises its long-term financial goals and focuses on scaling its profitable growth during the next strategy period Marimekko Board of Directors have decided on the new long-term financial goals for the company, raising the targets for net sales development and comparable operating profit margin. At the same time, the Board has set a direction for Marimekko’s next strategy period of 2023–2027, during which the company will focus on scaling the Marimekko business and growth especially in international markets, as described in a separate release. Marimekko will elaborate on the new long-term financial goals and strategic direction at the company’s first-ever Capital Markets Day on Wednesday, 14 September 2022. Marimekko’s long-term financial goals The new long-term...

Bidding process and auction for JATENZO (testosterone undecanoate capsules; C-III) projected to conclude late October 2022 NORTHBROOK, Ill., Sept. 05, 2022 (GLOBE NEWSWIRE) — Clarus Therapeutics Holdings, Inc. (Clarus) (OTC: CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen therapies, announced today that it, together with its wholly-owned subsidiary Clarus Therapeutics, Inc., has filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware (the Court). Clarus has also filed a motion seeking authorization to pursue an auction and sale process under Section 363 of the U.S. Bankruptcy Code of its sole commercial asset, JATENZO, that is approved for use by healthcare providers to treat testosterone deficiency...

— Up to 12-fold higher neutralizing antibody titers observed in participants who received SCB-2019 (CpG 1018/Alum) as a heterologous third dose after two doses of inactivated vaccine compared to a third dose of inactivated vaccine — –– Superior immune responses observed for SCB-2019 versus the inactivated vaccine booster against the original strain and Omicron subvariants — — Positive heterologous booster responses consistent with prior observations for homologous booster and in subjects with prior infection, underscoring the potential of SCB-2019 as a universal COVID-19 booster vaccine — SHANGHAI, China, Sept. 06, 2022 (GLOBE NEWSWIRE) — Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic...

GUADALAJARA, Mexico, Sept. 05, 2022 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announces preliminary terminal passenger traffic figures for the month of August 2022, which includes comparisons with the 2019 and 2021 figures to facilitate the reading and understanding of the passenger traffic trend. For August 2022, the total number of terminal passengers at GAP’s 12 Mexican airports increased by 19.8%, compared to the same period of 2019. Tijuana, Puerto Vallarta, Los Cabos and Guadalajara presented an increase in passenger traffic of 43.2%, 37.3%, 29.6% and 6.3% respectively, compared to August 2019.Passenger traffic 2022 compared to 2019 Domestic Terminal Passengers (in thousands):Airport Aug-19 Aug-22 % Change Jan-Aug 19 Jan-Aug 22 % ChangeGuadalajara 890.4 978.8 9.9% 6,929.5 7,021.2 1.3%Tijuana* 527.8 741.9 40.6% 3,960.1 5,316.1 34.2%Los...

Continuation of the analysis in view of the distribution of Grupo Éxito to GPA’s shareholders Paris, 5th September 2022, The Board of Directors of GPA, subsidiary of Casino Group, has announced that it is considering to distribute approximately 83% of the shares of Grupo Éxito to its shareholders and to retain a minority stake of approximately 13%, with a potential for monetization in the future. The Board of Directors of Casino met today and approved the principle of the proposed segregation of GPA and Grupo Éxito in order to unlock Grupo Éxito’s value. The distribution of Grupo Éxito’s shares to GPA’s shareholders would occur through the delivery of BDRs (Brazilian Depository Receipts) and ADRs (American Depository Receipts), consistent with GPA’s shareholder structure. Subject to the completion of the preparatory works and the...